In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37399557.
- Also identified by DOI 10.7326/J23-0042.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Huss V, Bower H, Hellgren K, et al; ARTIS group. <b>Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.</b> Ann Rheum Dis. 2023;82:911-919. 36868796.
Medical subject headings
- Janus Kinase Inhibitors
- Antirheumatic Agents
- Skin Neoplasms